Premium
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. Show more
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 31, 2025 NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar...
Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301...
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar...
BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.39 | -4.88110137672 | 7.99 | 8.535 | 6.995 | 1412761 | 7.64311069 | CS |
| 4 | 1.47 | 23.9804241436 | 6.13 | 8.535 | 5.189 | 1650986 | 6.70602478 | CS |
| 12 | 1.2 | 18.75 | 6.4 | 8.535 | 4.44 | 1675422 | 6.09572128 | CS |
| 26 | 0.5 | 7.04225352113 | 7.1 | 8.535 | 4.305 | 1483930 | 5.756114 | CS |
| 52 | -3.61 | -32.2033898305 | 11.21 | 19.34 | 4.305 | 1406752 | 7.08868384 | CS |
| 156 | -21.3569 | -73.7540966056 | 28.9569 | 43 | 4.305 | 1087582 | 14.38423789 | CS |
| 260 | -22.4 | -74.6666666667 | 30 | 78 | 4.305 | 983994 | 17.00152321 | CS |
| Symbole | Prix | Vol. |
|---|---|---|
| TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 729,72M |
| NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,54M |
| RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 338,75M |
| BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,29M |
| CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 234,8M |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
